This will play a video. - Photo of smiling adult female and male seniors, post-TAVR, who are standing up and doing yoga in class

SUPERIOR HEMODYNAMICS

Transcatheter Aortic Valve Implantation (TAVI) is now an option for symptomatic severe aortic stenosis patients at low risk for surgery.
Animation of Evolut Pro TAVR showing the three leaflets opening and closing into the aorta

Evolut TAVI Platform

Evolut™ TAVI is currently the only TAVI device to demonstrate hemodynamic superiority in a low risk clinical trial vs. SAVR at one year.1

LEARN ABOUT EVOLUT LOW RISK STUDY RESULTS FROM NEJM

SUPERIOR
EFFECTIVE ORIFICE AREAS
(EOA)

Evolut TAVI 2.3 cm2 vs. SAVR 2.0 cm2

15% Larger EOAs

Blue up arrow with 15% text inside and text stating larger EOAs beneath it

SUPERIOR Gradients 

Evolut TAVI 8.6 mm Hg vs. SAVR 11.2 mm Hg

23% Lower Gradients 

Blue down arrow with 23% text inside and text stating lower gradients beneath it

SAFE and EFFECTIVE

As demonstrated by all-cause mortality or disabling stroke, noninferior to SAVR at 24 months1

5.3% TAVI vs. 6.7% SAVR
n = 1,468

A box with text that reads 5.3 percent TAVR and a second box next to it reads 6.7 percent SAVR
See More Low Risk Data
Evolut TAVI compared to SAVR

EvolutTM TAVI showed lower mortality, fewer disabling strokes, and fewer heart failure rehospitalisations compared to SAVR2

he graph indicates that Evolut TAVR composite rate is 5.5 percent and the SAVR rate is 10.2%. This is 45% lower for the Evolut TAVR platform and is a difference of negative four point five percent with a P value of .002

FASTER RETURN TO AN ACTIVE LIFE

  • EVOLUT TAVI SUPERIOR TO SAVR
    in self-reported KCCQ measures at 30 days1
  • 58% SHORTER HOSPITAL STAY
    with TAVI procedures vs. SAVR procedures2
  • LOWER RATES OF HEART FAILURE REHOSPITALIZATION
    with Evolut TAVI vs. SAVR at one year2
A senior male TAVR patient who is happy and giving his girlfriend a side hug at the beach

References

1

Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.

2

Reardon MJ. The Evolut Low Risk Trial. Presented at ACC 2019; New Orleans, LA.